RecruitingAdvanced Solid Tumors
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
You may qualify if…
- ✓ Written informed consent.
- ✓ Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
- ✓ Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.
- ✓ Patients must have KRAS alterations.
- ✓ Participants are required to provide an archived tumor sample.
- ✓ Patients with a life expectancy ≥3 months.
- ✓ ECOG performance status score of 0 or 1.
- ✓ Patients must have at least one measurable lesion as defined by RECIST v1.1.
You may not qualify if…
- ✕ Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the absorption of the study drug.
- ✕ Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, or pan/multi-KRAS inhibitors.
- ✕ Known serious allergy to JAB-23E73 or excipient.
- ✕ Patients with primary central nervous system tumors.
- ✕ Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures or medical intervention.
- ✕ QT interval\>470 msec.
- ✕ LVEF ≤50% assessed by ECHO or MUGA.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06973564 · last updated 2026-01-16